scholarly article | Q13442814 |
P356 | DOI | 10.1586/ERP.10.56 |
P953 | full work available at URL | http://www.future-drugs.com/doi/abs/10.1586/erp.10.56 |
http://www.tandfonline.com/doi/pdf/10.1586/erp.10.56 | ||
P698 | PubMed publication ID | 20950069 |
P50 | author | Andrés Pichon Riviere | Q86047017 |
P2093 | author name string | Federico Augustovski | |
Osvaldo Ulises Garay | |||
Adolfo Rubinstein | |||
Joaquín E. Caporale | |||
P2860 | cites work | Cost and cost-effectiveness guidelines: which ones to use? | Q34174634 |
Health economic guidelines--similarities, differences and some implications | Q34436165 | ||
Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle | Q35925125 | ||
Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. | Q36948710 | ||
Can economic evaluation guidelines improve efficiency in resource allocation? The cases of Portugal, The Netherlands, Finland, and the United Kingdom | Q50129944 | ||
The development of health technology assessment in Brazil. | Q53100782 | ||
Health technology assessment in Mexico. | Q53101300 | ||
Where are the economic guidelines coming from? | Q73392116 | ||
Health-care decision-making processes in Latin America: problems and prospects for the use of economic evaluation | Q81451309 | ||
Key principles for the improved conduct of health technology assessments for resource allocation decisions | Q81581696 | ||
Using economic evidence in reimbursement decisions for health technologies: experience of 4 countries | Q84642969 | ||
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 525-537 | |
P577 | publication date | 2010-10-01 | |
P1433 | published in | Expert Review of Pharmacoeconomics & Outcomes Research | Q15734522 |
P1476 | title | Economic evaluation guidelines in Latin America: a current snapshot | |
P478 | volume | 10 |
Q38573098 | Cost effectiveness evaluation of a rotavirus vaccination program in Argentina |
Q38845478 | Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico. |
Q36089475 | Eliminating artificial trans fatty acids in Argentina: estimated effects on the burden of coronary heart disease and costs |
Q36266671 | Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model. |
Q41728685 | IMPLICATIONS OF GLOBAL PRICING POLICIES ON ACCESS TO INNOVATIVE DRUGS: THE CASE OF TRASTUZUMAB IN SEVEN LATIN AMERICAN COUNTRIES. |
Q52812131 | Measuring the Benefits of Healthcare: DALYs and QALYs - Does the Choice of Measure Matter? A Case Study of Two Preventive Interventions. |
Q51111203 | Medical devices: from licensing to coverage. highlights from Argentina, Brazil, Colombia and Mexico. |
Q29353660 | Oxytocin in Uniject Disposable Auto-Disable Injection System versus Standard Use for the Prevention of Postpartum Hemorrhage in Latin America and the Caribbean: A Cost-Effectiveness Analysis |
Q53141521 | Universal coverage with rising healthcare costs; health outcomes research value in decision-making in Latin America. |
Q92054533 | [Health impact assessment of the Program Healthy Centers in the Autonomous City of Buenos Aires, ArgentinaAvaliação do impacto na saúde do Programa Estações Saudáveis na Cidade Autônoma de Buenos Aires, Argentina] |
Search more.